In secondary MR, there is evidence of improvement in severity with treatment for heart failure and reduction in left chambers remodeling with ACE inhibitors/ARBs, sacubitril/valsartan, and SGLT2 inhibitors. The gene discussed is ACE; the disease is miotic rate.